FDA inspection
MBi Distributing Inc. dba MBi Nutraceuticals: FDA inspection ending May 17, 2001
FDA inspection 73673 · Voluntary Action Indicated (VAI) · Lindon, UT
Key facts
| Inspection ID | 73673 |
|---|---|
| Firm | MBi Distributing Inc. dba MBi Nutraceuticals |
| FEI number | 3005482889 |
| Address | 211 N 1800 W |
| City | Lindon |
| State | UT |
| ZIP | 84042-1627 |
| Fiscal year | 2001 |
| Inspection end date | May 17, 2001 |
| Classification | Voluntary Action Indicated (VAI) |
| Project area | Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs|OTC Drug Evaluation|Unapproved and Misbranded Drugs |
| Product type | Drugs |
At a glance
- None Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data